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Background
The knotty problem of dealing with children undergoing immu-
nosuppressive treatment for cancer to prevent and treat, but 
not overtreat, potential life-threatening infection continues to 
intrigue and enrage clinical academics working in this field. The 
challenges lie in reducing the chance of an infection develop-
ing and leaping upon infections quickly to maximize the likely 
outcomes but discontinuing antibiotic treatments and hospitali-
zation to reduce the adverse psychological, social, and medical 
effects of being an in-patient. A growing body of primary 
studies and systematic reviews is assisting with these areas and 
identifying where further studies are required.
Preventing infection
Prevention of infection has been addressed by reducing the 
chance of acquiring an infection and by using prophylactic anti-
bacterial therapy. Systematic reviews of the use of specialized 
“low-bacterial diets” to decrease the risk of bacterial transloca-
tion across the gut wall have demonstrated little benefit for this 
approach1, which is confirmed in a specific comparative study 
in children2. These diets are harder to adhere to for families, 
contain far less joy, and are convincingly unhelpful. Other 
traditional, but unevaluated, practices such as “protective” 
isolation or hospitalization and the wearing of facemasks or 
avoidance of companion animal contact deserve the same sort 
of scrutiny as “low bacterial diets” in the future.
The concept of infections being affected by gut bacteria is not 
without merit, though. Analysis of the gut microbiome in chil-
dren being treated for acute lymphoblastic leukemia (ALL), 
the commonest single childhood malignancy, shows associa-
tion between particular patterns of colonization and infection3. 
Evidence synthesis of trials of probiotics shows a reduction in 
fever episodes4, though there are few trials in children and 
a hint of “small study effects”, which may have produced 
overoptimistic results. The same review demonstrated a 
remarkably low level of probiotic-associated sepsis, and all 
infections were easily and effectively treated with antimicrobials. 
This element of iatrogenic harm from probiotics appears to be 
based more on fear than solid evidence.
Rather than introducing controlled bacteria, an opposing 
approach has been used in children at highest risk of invasive 
infection: the use of prophylactic antibiotics. A large systematic 
review of trials in all ages demonstrated a reduction in fever epi-
sodes, proven infections, and death5. There are very few studies 
in children, though; the only large, modern-era study did 
show benefit for levofloxacin in a group at particularly high risk 
of infection (ALL and relapsed, heavily immunosuppressed 
ALL patients)6. Whether this is the right way to use anti-
biotics remains hotly contested, as the use of prophylaxis 
raised the proportion of isolates resistant to the antibacteri-
als. Though this wasn’t a clinical problem in the time frame 
of the trial, commentators, particularly those who are in 
countries with high rates of antimicrobial resistance, raise valid 
questions around this approach7.
Despite the widespread use of granulocyte colony stimulating 
agents, very few recent studies have been undertaken to exam-
ine them. Systematic reviews from a decade ago found little 
evidence to support their prophylactic use in children8. Spe-
cific regimens have found benefit broadly in terms of side 
effects when treating neuroblastoma induction chemotherapy9, 
but broader studies have yet to provide convincing evidence 
of benefit with modern, restrictive, antibiotic stewardship 
approaches.
Antibacterial approaches
Antibiotic delivery to patients who present with signs of poten-
tial infection, which in this group is classically fever in the pres-
ence of neutropenia, is widely accepted to be a universal “good 
thing”10. There remains some reasonable debate as to whether 
the “one-hour window” for antibiotic delivery is useful: a very 
recent systematic review of well-conducted studies showed 
an association between longer duration to treatment and increased 
risk of adverse outcomes but could not draw a line in the sand 
at 60 minutes11. While there have been some approaches to 
define a group in whom no antibiotics are necessary, this hasn’t 
been shown to be practical. The focus has moved to defin-
ing how narrow a spectrum of antibacterial can be safely 
used12 and ways of discontinuing treatment quickly. Research 
has confirmed patients and their families want to be treated as 
safely as possible but get out of hospital as soon as they can to 
improve their life experience13,14.
The discontinuation drive forks at those attempts to define, at 
presentation of the feverish episode, a way of clarifying who 
doesn’t need intravenous antibiotics and admission; and attempts 
to describe who can have antibiotics stopped. Up-front clinical 
prediction models have been widely generated but infrequently 
tested and validated15. When they have, they have shown only 
moderate value and require refinement16,17. Practically, imple-
menting a method of risk stratifying and treating using such a 
rule has been shown to be relatively safe, both across all ages18 
and specifically in children19. The approaches tend to use 
a combination of factors related to the malignant diagno-
sis of the child, their social situation, and episode-related 
elements. In this way, those treated as out-patients would 
not have received conditioning chemotherapy for a hematopoi-
etic stem cell transplant, live hours from medical attention, 
or have arrived in hospital with septic shock and a need for 
inotropic support.
Stopping rules have been investigated relatively little, in com-
parison with other aspects of management, and a traditional 
approach of continuing antibacterials until the fever has set-
tled, often for 48 hours, and the bone marrow shows signs of 
recovery is still common practice10. Challenges to this have 
been made, questioning the need for count recovery in clinically 
well children20,21 or stopping treatments earlier when a defini-
tive viral infection without co-existing severe bacterial infection 
has been documented22. Such “enhanced stopping” approaches 
may be more effective than a risk stratification system, which at 
best affects 30% of patients. Other approaches which har-
ness dynamic changes in easily measurable serum biomarkers, 
such as procalcitonin, are also set for clinical trials in this group13.
Persistent fevers and fungus
As well as a group of children in whom a confirmed bacte-
rial infection requires ongoing antibacterial therapy, there is a 
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group with persistent fever in whom no clear cause is imme-
diately identified. The worry in these heavily immunocompro-
mised patients is of invasive fungal disease (IFD). A systematic 
review pulled all of the available data together to try to distin-
guish those who would be at higher and lower risk in order to 
rationally target the use of empirical antifungal drugs, medica-
tions which have high costs and tricky side effects23. The review 
showed a disappointing absence of well-conducted studies and 
failed to describe really clear groups which had very low or 
very high risks. Relapsed and intensively treated leukemias, 
those where neutropenia was expected to be profound and 
long-lasting, those undergoing treatment with high doses of 
corticosteroids, and those with graft-versus-host disease were 
confirmed to be the greatest worry. With difficulty in determining 
risk groups precisely once again facing clinicians, attention has 
been brought to bear on the use of empiric antifungals, where the 
treatment is given to everyone at moderate–high risk, or the use 
of a pre-emptive approach, in which only in the presence of 
early imaging or biomarker signs of invasive fungal infection 
are the antifungal agents commenced. Both strategies have been 
used, and a randomized trial in children seems to suggest that 
they have equivalent safety, with a reduced use of medication 
in the pre-emptive arm24. The key element in this pre-emptive 
approach is “screening” for hints of infection and looking to rule 
out an emerging IFD. There is a growing body of tests based on 
bodily fluids, blood, and alveolar or cerebrospinal fluid, which 
could make this approach even more effective. Combining mark-
ers of the most common invasive species, and broad pan-fungal 
PCR detection approaches, could be this improvement25. 
Even with this suggestion of future improvement, there 
remains some concern; the results of a single, relatively 
small trial should not determine treatment in a condition with 
a very high fatality rate and, as with many areas of medi-
cine, it may remain debated hotly until further studies are 
undertaken.
Conclusion
Infection in the child undergoing cancer treatment remains a 
frequent, occasionally fatal, and better manageable complica-
tion of therapy. The current standard of care is that children 
with cancer who have fever and neutropenia are evaluated 
promptly and antibiotics are initiated. This may be in the 
hospital or at home, depending on the underlying diagnosis of the 
child, their social situation, and episode-related elements. In the 
future, we may be modifying the microbiome with probiot-
ics, giving judicious prophylaxis to patients at highest risk of 
infection, sliding a small proportion home from the assess-
ment cubicles, and quickly striking through the prescriptions 
of those who don’t have signs of serious infections, perhaps 
guided by inflammatory biomarkers. Persistent fevers will 
remain troubling to us, but more research will be undertaken to 
try to elucidate who is developing invasive fungal infections and 
how we can effectively treat them.
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